April 8, 2020  Last Update: November 12, 2019, 4:01 pm

Hide Your Vikes! DEA Reclassifies Hydrocodone Products

"Hide Your Vikes" concept art created in response to the threat of reclassifying Vicodin as a Schedule II controlled substance.

“Hide Your Vikes” concept art created in response to the DEA’s threat to reclassify Vicodin as a Schedule II controlled substance.

The DEA wants to increase controls over prescription painkillers containing hydrocodone. Under the proposed changes, hydrocodone-containing drugs like Vicodin, Xodol ,and Lortab would be reclassified the same status as hydrocodone itself, in an attempt to restrict diversion from legitimate distribution to the black market.

Most drugs known to contain hydrocodone actually contain a mixture of ingredients . Vicodin, for example, is a combination of hydrocodone and acetaminophen. Hydrocodone itself is already Schedule II, but until last week’s release of Zohydro, there were no single-entity hydrocodone drugs on the market.

The proposal would move “hydrocodone combination products” (HCPs) from Schedule III classification to Schedule II. Both Schedule III and Schedule II drugs are considered to have legitimate, legal medical uses; what differs is their potential for abuse and diversion to the black market.

Hide your Vikes: hydrocodone-containing drugs to be re-classified as Schedule II

The DEA claims there’s evidence to show that Hydrocodone Containing Products are now among the “top 10 most frequently encountered drugs” in enforcement actions, and that self-reported non-medical HCP use has increased by 35 percent between 2002 and 2012.

According to the data from the National Survey on Drug Use and Health … in 2004, over 17.7 million Americans age 12 years or older reported lifetime nonmedical use of HCPs as compared to over 11.9 million reported for oxycodone products. In 2012, the corresponding data for HCPs and oxycodone products were over 25.6 and 16 million, respectively.



  • ref: DEA Proposal
  • The DEA has opened up the request to public comments, which it will accept until April 27. Comments may be submitted at www.regulations.gov


  1. […] also covered the DEA’s reclassification of hydrocodone-containing products to Schedule II, where hydrocodone itself is […]

Speak Your Mind


You are reading the category "DEA - From the world of drug enforcement, including the DEA and local law enforcement." which is a PERMANENT category.